Articles tagged with Molecular Imaging
A novel imaging agent, Zr-89-Df-IAB2M, has been shown to detect metastasis of prostate cancer in both bone and soft tissue lesions with high accuracy. The agent targets PSMA on the exterior of prostate cancer cells, allowing for faster and more accurate detection than conventional methods.
Researchers have successfully used PET imaging to visualize cardiac amyloidosis, a condition characterized by abnormal protein deposits in the heart. The study showed that F-18-florbetaben PET imaging can accurately identify and differentiate between cardiac amyloidosis and hypertensive heart disease.
The study demonstrates the effectiveness of activity-based probes in detecting early signs of atherosclerosis. By targeting cysteine cathepsins, the probes image activated macrophage populations using optical and PET/CT methods, providing real-time monitoring of disease progression and therapeutic responses.
Researchers developed a new radiotracer that safely and effectively maps sentinel lymph nodes in breast cancer patients. The study demonstrated the tracer's ability to provide clear SLN imaging with high detection rates.
The SNMMI-TS awarded Lynne Roy, Crystal Botkin, David Campbell, Marcia Hess Smith, Deborah Gibbs, Dmitry D. Beyder, and Aaron Scott for their exceptional contributions to the field of nuclear medicine technology, including education, service, and leadership.
SNMMI recognized Peter Herscovitch and Satoshi Minoshima for their contributions to the field of nuclear medicine through various awards. Dominique Delbeke received the Presidential Distinguished Educator Award for her work as editor of The Journal of Nuclear Medicine.
Researchers have developed a new device that enables existing breast cancer imagers to provide up to six times better contrast of tumors in the breast while maintaining the same or better image quality. The Variable Angle Slant Hole Collimator reduces radiation dose to patients by half, potentially improving imaging of other organs.
A new study by the Society of Nuclear Medicine and Molecular Imaging shows that PET/CT imaging using prostate-specific membrane antigen leads to highly accurate tumor detection and delineation, with a 67% accuracy rate.
A novel PET imaging study reveals a significant correlation between increased tau and decreased metabolic activity in the brains of living Alzheimer's patients, indicating clear signs of neurodegeneration. The study measures amyloid plaques, tau tangles, and metabolic activity using three different radiotracers.
A novel CT-based calculation method, SULps, accurately measures lean body mass using computed tomography, leading to more precise PET imaging results. This improvement enables better staging of disease and therapy monitoring in cancer patients.
The novel portable diagnostic tool offers a multi-dimensional look at the body by combining optical and gamma imaging, allowing physicians to visualize molecular data alongside surface organ images. Clinical pilot studies have shown promising results in imaging lymphatic and thyroid tissue, as well as tear ducts.
Researchers used FDG-PET imaging to monitor atezolizumab, an immune checkpoint inhibitor, in NSCLC patients. The study found that higher baseline tumor volumes were predictive of reduced patient survival, and further increase in tumor volume after treatment was associated with decreased survival.
Researchers used PET and SPECT to tailor radionuclide treatment for neuroendocrine cancer patients, reducing the risk of toxicity. The study showed that personalized dosimetry led to a significant alteration in radiotherapy doses, with some patients receiving reduced or increased doses.
The Education and Research Foundation for Nuclear Medicine and Molecular Imaging honored Dr. H. William Strauss with the 2016 Benedict Cassen Prize for his seminal studies in cardiovascular nuclear medicine. This award recognizes his work that has greatly advanced nuclear medicine science and had a high clinical impact.
A new PET study reveals that tau protein tangles in the brain may be driving the neurodegeneration behind Alzheimer's disease. The research found a significant correlation between increased tau and decreased metabolic activity in the brain, suggesting that tau imaging could be used to detect neuronal injury earlier than amyloid imaging.
Ross McDougall, a renowned Stanford professor, has been honored with the 2016 Georg Charles de Hevesy Nuclear Pioneer Award for his groundbreaking work in nuclear medicine. With over 160 peer-reviewed publications and three textbooks on thyroid disease, he has made significant contributions to advancing the field of nuclear medicine.
A recent study using PET/CT imaging found that the brains of recovering alcoholics have adapted to chemical dependency by significantly hindering metabotropic glutamate receptor subtype 5 (mGluR5) receptors, reducing cravings. This discovery could lead to new targeted drugs to limit receptor activity in patients at risk of relapse.
Peter S. Conti, MD, PhD, receives the prestigious Paul C. Aebersold Award for his groundbreaking work in developing novel diagnostic imaging agents for oncology applications. His research focuses on PET imaging and gene expression, advancing the field of nuclear medicine and molecular imaging.
Researchers developed pretargeted radioimmunotherapy, combining an anti-GPA33 antibody with radionuclide agents to deliver radiation directly to tumors. In mouse models, the technique achieved complete remission of colorectal cancer without collateral toxicity.
A genetic blood test called NETest measures specific genes in the blood that define and predict responsiveness to PRRT. The test was found to be more than 90% accurate in predicting therapy response and non-response, with 73% of low-grade tumors responding to treatment.
Researchers developed PET tracers that can visualize inflammatory disease and evaluate next-generation MS therapies. The study found that the compounds could detect an increase in S1P1 expression in animals with an inflammatory response, suggesting a promising approach for imaging MS and other inflammatory diseases.
A recent study found that Ga-68 DOTATATE PET/CT scans are superior to In-111 pentetreotide scans in detecting neuroendocrine tumors, leading to improved treatment management and patient outcomes. The imaging method demonstrated no significant toxicity, lower radiation exposure, and increased accuracy.
A recent study by researchers at the University of Liverpool analyzed data from 157 ecstasy users and 148 controls to examine the effect of ecstasy on the brain. The study found significant reductions in serotonin transport in ecstasy users, which may contribute to cognitive deficits and mood changes.
Researchers have developed a pill that can selectively target cancer cells, providing clearer images and reducing the risk of false positives. The oral agent uses near-infrared light to bind to tumors, allowing for more accurate diagnoses and potentially leading to improved treatment outcomes.
Researchers found that genetics play a major role in the bilateral parietal lobes and left temporal lobe, while environment dominates other brain regions. This study provides insights into how nature and environment interact to shape our brains, potentially informing the development of neurological and psychiatric disorders.
A recent study shows that a PET/CT scan using F-18-DCFBC is significantly more effective in detecting metastatic prostate cancer than other detection methods. The radiotracer targets prostate-specific membrane antigen, which is expressed in the majority of prostate cancers and associated with metastatic spread.
A recent study found that PET/CT and whole-body MRI detect extraskeletal disease, changing cancer management. Combined administration of F-18 sodium fluoride (NaF) and F-18 fluorodeoxyglucose (FDG) in a single PET/CT scan showed higher sensitivity and accuracy than alternative methods.
A new class of light-emitting quantum dots has been introduced, enabling precise control over their fluorescence brightness across a range of colors. This innovation allows for more accurate measurements of molecules in diseased tissue and improved quantitative imaging capabilities.
A new imaging agent, Ga-68 PSMA, significantly improved detection of early recurrent prostate cancer in a study published in The Journal of Nuclear Medicine. The agent was found to detect sites of possible recurrence in 50% of patients with low PSA levels, compared to only 12.5% for another widely used agent.
Researchers developed a molecular imaging biomarker that detects fast-growing primary prostate cancer and distinguishes it from benign prostate lesions. The new PSMA-based PET imaging technique was more specific than MR imaging for detecting clinically significant high-grade prostate cancer lesions.
Scientists have successfully imaged ultrafast unidirectionally rotating molecules at 100 billion per second, revealing a quantum wave-like nature. The high-resolution imaging reveals rotational wave packets with distinct angular velocities, showcasing the transition from quantum to classical behavior.
A new molecular imaging agent has been developed to detect prostate cancer that has spread to other tissues. The agent targets the PSMA enzyme, which is associated with prostate cancer, and has shown high accuracy in detecting disease sites, including those not identified by conventional methods.
The hybrid scanner combines conventional MRI, hyperpolarized MRI, positron imaging, luminescence imaging, and fluorescence microscopy to provide high-resolution multimodal intra-vital imaging. This allows researchers to study tumor biology and develop targeted therapies by analyzing the co-registration of multiple imaging data lines.
Researchers used PET/CT with Ga-68 DOTATOC to detect primary tumors in patients with metastatic neuroendocrine cancer. The study found that 28% of patients underwent a major change in cancer management due to the imaging technique.
A novel PET technique tracks microglial activation in response to endotoxin, shedding light on neuroinflammatory diseases like Alzheimer's and depression. The study's findings could lead to new drug treatments by targeting immune dysfunction.
A novel radionuclide drug, PSMA-617, has been developed to target prostate-specific membrane antigen (PSMA) on prostate cancer cells, allowing for personalized diagnosis and therapy. The drug showed promising results in a human clinical trial, with effective imaging and therapeutic effects.
A specialized PET tracer has been developed to visualize the function of nerve cells that lead to neuronal loss and cognitive decline in neurodegenerative diseases. The tracer binds to a transporter of the neurotransmitter acetylcholine, allowing for the quantification of cholinergic neuron loss and its effects on cognition.
Researchers have developed a cloud-based software that analyzes and standardizes PET imaging data, allowing for earlier and more accurate diagnoses of Alzheimer's disease. The program uses machine learning to compare patients' scans with normal and abnormal scans, providing consistent results and quantifying PET data accurately.
Researchers developed PSMA-617, a theranostic drug that detects prostate cancer and targets enzyme on cancer cells. The technology shows substantial reduction in radiotracer uptake and significant decrease in PSMA in blood after therapy, indicating positive response.
A new study found that PET/CT scans are highly sensitive for detecting relapsed non-Hodgkin lymphoma, with a sensitivity rate of 95.1%. This breakthrough has significant implications for patient care, as early diagnosis can lead to improved treatment outcomes and longer survival rates.
Scientists have developed a novel PET tracer that can pinpoint thrombi throughout the body with over 97% accuracy. The tracer, Cu-64 FBP8, targets fibrin in blood clots and reflects thrombus age, enabling clinicians to choose more effective treatments.
Researchers have developed three new MRI agents that successfully target the prostate-specific membrane antigen (PSMA) biomarker in multiple cancers. PSMA is found in both primary and metastatic prostate tumors, as well as in newly developing blood vessels of many non-prostate cancers.
A new technique combines dynamic PET imaging with parametric tumor mapping to detect tumors and metastases throughout the body, providing quantitative evaluation and improved contrast. This method has the potential to be used for early diagnosis and more accurate prognosis of various cancers.
A new theranostic agent, I-124 PEG-AVP0458, has shown promise in targeting both ovarian and prostate cancer cells for imaging and treatment. The drug compound attaches itself to the targeted tumor sites via positron emission tomography (PET) scanners, enabling personalized cancer therapy.
A new molecular imaging scan detects dangerous protein deposits in the heart, significantly increasing cardiac risk. The scan uses a widely available agent to assess amyloid buildup and predict future heart attacks.
Townsend's contributions to nuclear medicine have been transformative, introducing 3D PET imaging and the combined PET/CT scanner. His work has improved the signal-to-noise of reconstructed images without increasing detector material cost.
Phelps was recognized for his contributions to nuclear medicine and molecular imaging, including the invention of PET scanners. His work has improved outcomes for patients with cancer, neurological disorders, and cardiovascular disease.
A new non-invasive PET scan with C-11-vorozole detects aromatase in all body organs, potentially identifying cancer patients who may benefit from aromatase inhibitor treatment. The study also finds sex-dependent differences in radiation exposure and hormonal status.
A recent study found that the Ga-68-PSMA-ligand PET/CT detected a large number of positive findings in patients with biochemical recurrence after radical prostatectomy, particularly at low PSA-values. The tracer's higher detection rates compared to other imaging methods suggest an early detection advantage for further clinical management.
François Légaré, an INRS researcher, has been awarded the 2015 Herzberg Medal for his work in ultrafast molecular imaging. His research team made significant breakthroughs in dynamic imaging, capturing images of molecular reactions at unprecedented resolution.
Fourth and subsequent PET/CT scans improved clinical assessment and management change in lung cancer patients, with 52.28% positive and 47.7% negative results for recurrence or metastasis. The scans resulted in treatment changes in 28.1% of cases, with new treatments initiated in 20.4%.
Researchers from Berkeley Lab presented on severe weather events in a changing climate, novel technologies for exploring uncultivated microorganisms, and future of accelerators. They also discussed battery innovations and what to expect from the LHC's second run.
A novel radioguided surgery technique using Y-90 DOTATOC can effectively identify residual cancer cells during brain tumor surgery, reducing healthy tissue removal. The study's findings suggest the potential for improved resection margins and enhanced patient outcomes.
Researchers develop a new approach to customize nuclear medicine treatment for cancer, using targeted alpha therapy with customized radiolabeled antibody cocktails. This method has great potential for treating various diseases, including those with disseminated tumor cells.
A new study shows a novel molecular imaging drug is effective in detecting early prostate cancer in soft tissue, lymph nodes, and bone. The drug, Tc-99m MIP-1404, has favorable pharmacokinetics and biodistribution, representing a breakthrough in prostate cancer imaging.
Researchers found that PET/CT imaging can help diagnose more aggressive tumors in young breast cancer patients, upstaging 21% of initial diagnoses. The study suggests considering patient age as a factor in staging decisions.
Scientists have developed a new generation of hyperpolarizing agents that can be used to dramatically enhance the signal intensity of imaged body tissues without presenting any danger to the patient. The HYPSOs are made from a fine, white, porous powder containing tracking molecules, which act as markers for imaging.
The Society of Nuclear Medicine and Molecular Imaging has announced the 2014-2016 Wagner-Torizuka Fellowship recipients, which provide two-year fellowships to support Japanese physicians in early stages of their careers. The fellows focus on functional imaging using modalities such as PET/CT and SPECT/CT to elucidate pathophysiology of...
A new study using PET/CT with FDG-labeled leucocytes has detected infection in acute pancreatitis patients, distinguishing between infected and non-infected fluid collections. This non-invasive method may quickly rule out active infection and guide treatment decisions.
The 2014 SNMMI Annual Meeting showcased over 100 scientific sessions, 750 oral presentations, and 1,155 posters on molecular imaging technologies, clinical applications, and translational research. The meeting also featured notable lectures and awards, including the Henry N. Wagner Jr. Lectureship and the Benedict Cassen Prize.